SGLT2 inhibitors

GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview

October 15, 2025 // 0 Comments

Glucagon-like peptide-1 receptor agonists and sodium/glucose cotransporter 2 (SGLT2) inhibitors can improve outcomes in patients with type 2 diabetes. Using a nationwide [...]

Why Can’t We Flozinate? Reflections on Our Inability to Optimally Prescribe SGLT2 Inhibitors to the Patients That Need Them Most

September 20, 2023 // 0 Comments

Dr. James Torain is a second-year nephrology fellow at Duke University Hospital. He currently has an interest in implementation of home dialysis modalities. Health [...]

Highlights from the June 2022 Issue

June 1, 2022 // 0 Comments

Editor’s Note: We asked authors of Original Investigations to provide short plain-language summaries that would briefly summarize what inspired their study, the basic [...]

#NephMadness 2020: Thinking Outside The Paint – SGLT2 Inhibitors for Patients Without Diabetes Mellitus?

April 29, 2020 // 0 Comments

Brendon Neuen @brendonneuen Brendon Neuen is an academic nephrology registrar at Royal North Shore Hospital and an NHMRC Postgraduate Scholar at The George Institute in [...]

AJKD Blog

Official Blog of the American Journal of Kidney Diseases

SGLT2 inhibitors

GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview

Why Can’t We Flozinate? Reflections on Our Inability to Optimally Prescribe SGLT2 Inhibitors to the Patients That Need Them Most

Highlights from the June 2022 Issue

#NephMadness 2020: Thinking Outside The Paint – SGLT2 Inhibitors for Patients Without Diabetes Mellitus?